NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50242-0140-01 | 50242-0140 | Vismodegib | Erivedge | 150.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Jan 30, 2012 | In Use | |
72694-0879-10 | 72694-0879 | Vorasidenib | VORANIGO | 10.0 mg/1 | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Oral | Aug 7, 2024 | In Use | |
72694-0728-40 | 72694-0728 | Vorasidenib | VORANIGO | 40.0 mg/1 | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Oral | Aug 7, 2024 | In Use | |
00006-0568-40 | 00006-0568 | Vorinostat | Zolinza | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | HDAC | Oral | Oct 6, 2006 | In Use | |
68727-0950-02 | 68727-0950 | Zanidatamab-hrii | ZIIHERA | 50.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2 | Intravenous | Nov 20, 2024 | In Use | |
72579-0011-02 | 72579-0011 | Zanubrutinib | BRUKINSA | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Nov 14, 2019 | In Use | |
72579-0011-01 | 72579-0011 | Zanubrutinib | BRUKINSA | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Oral | Nov 14, 2019 | Sep 30, 2021 | In Use |
71837-1000-02 | 71837-1000 | Zenocutuzumab | BIZENGRI | 20.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2, HER3 | Intravenous | Dec 16, 2024 | In Use | |
83077-0100-02 | 83077-0100 | Zenocutuzumab | BIZENGRI | 20.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2, HER3 | Intravenous | Dec 4, 2024 | In Use | |
00024-5840-01 | 00024-5840 | ziv-Aflibercept | Zaltrap | 100.0 mg/4mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug 3, 2012 | In Use | |
00024-5840-03 | 00024-5840 | ziv-Aflibercept | Zaltrap | 100.0 mg/4mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug 3, 2012 | Nov 27, 2019 | In Use |
00024-5841-01 | 00024-5841 | ziv-Aflibercept | Zaltrap | 200.0 mg/8mL, 200.0 mg/8mL | Chemotherapy | Recombinant Fusion Protein | VEGF-IgG1 | Intravenous | Aug 3, 2012 | In Use | |
00469-3425-10 | 00469-3425 | ZOLBETUXIMAB | VYLOY | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CLDN18.2 | Intravenous | Oct 24, 2024 | In Use | |
00469-4425-30 | 00469-4425 | ZOLBETUXIMAB | VYLOY | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CLDN18.2 | Intravenous | Apr 24, 2025 | In Use | |
17478-0327-05 | 17478-0327 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 22, 2014 | In Use | ||
64679-0186-01 | 64679-0186 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Mar 2, 2013 | In Use | ||
68083-0142-01 | 68083-0142 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/100mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jul 5, 2018 | In Use | ||
55111-0685-07 | 55111-0685 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Mar 4, 2013 | In Use | ||
23155-0170-31 | 23155-0170 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Aug 31, 2023 | In Use | ||
17478-0327-45 | 17478-0327 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 22, 2014 | In Use | ||
47335-0962-41 | 47335-0962 | Zoledronic Acid | Zoledronic Acid | Ancillary Therapy | Bisphosphonate | intravenous | Mar 4, 2013 | Dec 31, 2014 | No Longer Used | ||
45963-0440-55 | 45963-0440 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Apr 13, 2015 | May 31, 2019 | No Longer Used | |
72603-0198-01 | 72603-0198 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov 1, 2023 | In Use | ||
60505-6110-00 | 60505-6110 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Mar 24, 2017 | In Use | ||
47335-0035-40 | 47335-0035 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Mar 4, 2013 | Sep 30, 2015 | No Longer Used |
Found 11564 results — Export these results